In December 2019, a novel coronavirus emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency [@bib0001],[@bib0002]. This coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (formerly 2019-nCoV), is responsible for respiratory infections including pneumonia, with an estimated mortality rate of approximately 2--2.5%, increasing with age and the presence of underlying diseases. In the first days of March 2020, an estimated 89 068 cases had been confirmed worldwide by the World Health Organization (WHO) (a number likely underestimated due to the existence of asymptomatic carriers) and the epidemic has already left 3046 dead from coronavirus disease 2019 (COVID-19), the majority of them occurring in China. Because COVID-19 is now becoming pandemic, and in the absence of a known validated efficient therapy, efforts of laboratories and medical teams have focused on repurposing US Food and Drug Administration (FDA)-approved drugs to treat the most severe COVID-19 cases. Drug repurposing is an effective way to quickly identify therapeutic drugs with a known safety profile to treat an emerging disease. Chloroquine/hydroxychloroquine, a front-line drug used in the treatment and prophylaxis of malaria as well as in autoimmune diseases, has been shown to inhibit the replication of several DNA and RNA viruses, including most human coronaviruses [@bib0003]. Recently, chloroquine was found to inhibit SARS-CoV-2 in vitro, and its hydroxylated form has been proposed as a possible therapy to treat patients infected with SARS-CoV-2 [@bib0004],[@bib0005]. In this context, other drugs also showed significant efficacy against SARS-Cov-2 in vitro, including remdesivir, lopinavir, ribavirin and ritonavir ([https://drugvirus.info/](http://www.drugvirus.info/){#interref0001a}) [@bib0006].

Teicoplanin, a glycopeptide antibiotic routinely used to treat bacterial infections, was found to be active in vitro against SARS-CoV and has joined the list of molecules that could be used in the therapeutic arsenal against COVID-19 [@bib0007]. This antibiotic, currently used in the treatment of Gram-positive bacterial infections, especially staphylococcal infections, has already shown efficacy against various viruses such as Ebola virus, influenza virus, flavivirus, hepatitis C virus and human immunodeficiency virus (HIV) as well as coronaviruses such as Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV [@bib0008],[@bib0009]. A patent was filed for the treatment of infection caused by MERS-CoV in 2016 [@bib0010]. According to Zhou et al., in coronaviruses teicoplanin acts on an early stage of the viral life cycle by inhibiting the low-pH cleavage of the viral spike protein by cathepsin L in the late endosomes, thereby preventing the release of genomic viral RNA and continuation of the virus replication cycle [@bib0008]. A recent study by the same authors showed that this activity was conserved against SARS-Cov-2 (the target sequence that serves as the cleavage site for cathepsin L is conserved among SARS-CoV spike protein) [@bib0007]. The concentration of teicoplanin required to inhibit 50% of viruses (IC~50~) in vitro was 1.66 µM, which is much lower than the concentration reached in human blood (8.78 µM for a daily dose of 400 mg) [@bib0007]. These preliminary results now need to be confirmed in a randomised clinical trial.

Based on our experience of teicoplanin use in the treatment of infectious diseases, we encourage further investigation of the antiviral effect of this molecule on SARS-CoV-2 and suggest teicoplanin as another potential alternative for the treatment of COVID-19.
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